Carfilzomib, Dexamethasone, and Daratumumab (KdD) Versus Carfilzomib and Dexamethasone (Kd) in Relapsed or Refractory Multiple Myeloma (RRMM): Subgroup Analysis of the Phase 3 CANDOR Study by Number of Prior Lines of Therapy (pLOTs) and Prior Therapies

被引：0

作者：

Quach, Hang ^{[1
]}

Nooka, Ajay ^{[2
]}

Samoylova, Olga ^{[3
]}

Venner, Christopher ^{[4
]}

Kim, Kihyun ^{[5
]}

Facon, Thierry ^{[6
]}

Spencer, Andrew ^{[7
]}

Usmani, Saad ^{[8
]}

Grosicki, Sebastian ^{[9
]}

Suzuki, Kenshi ^{[10
]}

Delimpasi, Sosana ^{[11
]}

Weisel, Katja ^{[12
]}

Obreja, Mihaela ^{[13
]}

Zahlten-Kumeli, Anita ^{[13
]}

Mateos, Maria-Victoria ^{[14
]}

机构：

[1] Univ Melbourne, St Vincents Hosp, Melbourne, Vic, Australia

[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[3] Nizhniy Novgorod Reg Clin Hosp, Nizniy Novgorod, Russia

[4] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada

[5] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea

[6] Hop Claude Huriez, Lille, France

[7] Monash Univ, Alfred Hlth, Melbourne, Vic, Australia

[8] Atrium Hlth, Charlotte, NC USA

[9] Silesian Med Univ Katowice, Katowice, Poland

[10] Japanese Red Cross Med Ctr, Tokyo, Japan

[11] Gen Hosp Evangelismos, Athens, Greece

[12] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[13] Amgen Inc, Thousand Oaks, CA 91320 USA

[14] Univ Hosp Salamanca IBSAL, Salamanca, Spain

来源：

关键词：

CANDOR; multiple myeloma; carfilzomib; daratumumab; lenalidomide; bortezomib; MM;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-128

引用

页码：S294 / S294

页数：1